Prime Medicine PRME Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's accretion (amortization) of discounts and premiums, investments?
- Prime Medicine (PRME) reported accretion (amortization) of discounts and premiums, investments of $460K in Q1 2026.
- How has Prime Medicine's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Prime Medicine's accretion (amortization) of discounts and premiums, investments increased by 35.7% year-over-year, from $339K to $460K.
- What is the long-term trend for Prime Medicine's accretion (amortization) of discounts and premiums, investments?
- Over 2 years (2023 to 2025), Prime Medicine's accretion (amortization) of discounts and premiums, investments has grown at a -33.9% compound annual growth rate (CAGR), from $5.68M to $2.48M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the periodic adjustment to the carrying value of investment securities held by the company to account for the amortization of premiums or the accretion of discounts. It reflects the systematic recognition of the difference between the purchase price and the face value of debt instruments over their remaining term. This adjustment is essential for accurately reporting interest income and the effective yield of the investment portfolio.